Sarepta Therapeutics Inc. (NASDAQ:SRPT) – Investment analysts at Wedbush lowered their Q3 2016 EPS estimates for shares of Sarepta Therapeutics in a research note issued on Tuesday. Wedbush analyst H. Behanna now expects that the firm will post earnings of ($1.26) per share for the quarter, down from their prior forecast of ($1.23). Wedbush currently has a “Outperform” rating and a $66.00 target price on the stock. Wedbush also issued estimates for Sarepta Therapeutics’ Q4 2016 earnings at ($1.18) EPS, FY2016 earnings at ($5.08) EPS, Q1 2017 earnings at ($0.80) EPS, Q2 2017 earnings at ($0.85) EPS, Q3 2017 earnings at ($0.78) EPS, Q4 2017 earnings at ($0.84) EPS, FY2017 earnings at ($3.27) EPS, FY2018 earnings at ($2.01) EPS, FY2019 earnings at $0.70 EPS and FY2020 earnings at $2.18 EPS.

Several other equities analysts have also issued reports on SRPT. Oppenheimer Holdings Inc. reaffirmed a “buy” rating and set a $60.00 price target on shares of Sarepta Therapeutics in a research note on Sunday, July 17th. Piper Jaffray Cos. reaffirmed a “sell” rating and set a $6.00 price target on shares of Sarepta Therapeutics in a research note on Saturday, June 4th. Robert W. Baird reaffirmed an “outperform” rating and set a $23.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, May 26th. Vetr lowered Sarepta Therapeutics from a “buy” rating to a “strong sell” rating and set a $17.28 price target on the stock. in a research note on Wednesday, June 8th. Finally, Cowen and Company reaffirmed a “hold” rating on shares of Sarepta Therapeutics in a research note on Thursday, May 26th. Two analysts have rated the stock with a sell rating, four have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. Sarepta Therapeutics has a consensus rating of “Buy” and a consensus target price of $51.01.

Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded up 6.55% during midday trading on Thursday, hitting $59.90. The stock had a trading volume of 5,206,349 shares. Sarepta Therapeutics has a one year low of $8.00 and a one year high of $60.00. The company’s market capitalization is $2.87 billion. The firm’s 50-day moving average is $29.05 and its 200 day moving average is $21.62.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/q3-2016-earnings-estimate-for-sarepta-therapeutics-inc-srpt-issued-by-wedbush.html

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.19) by $0.16. During the same quarter in the prior year, the firm earned ($0.87) earnings per share.

In other Sarepta Therapeutics news, SVP David T. Howton sold 9,304 shares of the firm’s stock in a transaction that occurred on Monday, September 19th. The stock was sold at an average price of $50.00, for a total value of $465,200.00. Following the completion of the transaction, the senior vice president now directly owns 11,168 shares in the company, valued at $558,400. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Jayant Aphale sold 35,000 shares of the firm’s stock in a transaction that occurred on Monday, September 19th. The shares were sold at an average price of $50.00, for a total value of $1,750,000.00. Following the completion of the transaction, the vice president now owns 21,490 shares of the company’s stock, valued at $1,074,500. The disclosure for this sale can be found here. 10.90% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Harbour Capital Advisors LLC acquired a new stake in Sarepta Therapeutics during the second quarter worth about $335,000. Schwab Charles Investment Management Inc. boosted its stake in Sarepta Therapeutics by 1.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 153,816 shares of the company’s stock worth $2,934,000 after buying an additional 2,766 shares during the last quarter. Stifel Financial Corp boosted its stake in Sarepta Therapeutics by 5.4% in the second quarter. Stifel Financial Corp now owns 23,076 shares of the company’s stock worth $441,000 after buying an additional 1,178 shares during the last quarter. American Century Companies Inc. acquired a new stake in Sarepta Therapeutics during the second quarter worth about $651,000. Finally, First Allied Advisory Services Inc. boosted its stake in Sarepta Therapeutics by 6.7% in the second quarter. First Allied Advisory Services Inc. now owns 12,800 shares of the company’s stock worth $245,000 after buying an additional 800 shares during the last quarter. Hedge funds and other institutional investors own 72.09% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.